Based in San Francisco, Elive’s patented, first of its kind synthetic biology platform is customisable for in situ production of drugs using commensals.
ELBiT-588, the lead candidate, is a microbe engineered with metabolic pathway to produce an FDA approved small molecule drug for LS-SCLC, equipped with ciruits and switches to "sense & produce" drug at the site and also induce immunogenic cell death, formulated as a nebulizer, for long term resident therapy to improve patient quality of life at affordable cost.
